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Abstract
Background: There is increasing evidence supporting the concept of cancer stem cells (CSCs), which are responsible
for the initiation, growth and metastasis of tumors. CSCs are thus considered the target for future cancer therapies. To
achieve this goal, identifying potential therapeutic targets for CSCs is essential.
Methods: We used a natural product of vitamin E, gamma tocotrienol (gamma-T3), to treat mammospheres and
spheres from colon and cervical cancers. Western blotting and real-time RT-PCR were employed to identify the gene
and protein targets of gamma-T3 in mammospheres.
Results: We found that mammosphere growth was inhibited in a dose dependent manner, with total inhibition at
high doses. Gamma-T3 also inhibited sphere growth in two other human epithelial cancers, colon and cervix. Our
results suggested that both Src homology 2 domain-containing phosphatase 1 (SHP1) and 2 (SHP2) were affected by
gamma-T3 which was accompanied by a decrease in K- and H-Ras gene expression and phosphorylated ERK protein
levels in a dose dependent way. In contrast, expression of self-renewal genes TGF-beta and LIF, as well as ESR signal
pathways were not affected by the treatment. These results suggest that gamma-T3 specifically targets SHP2 and the
RAS/ERK signaling pathway.
Conclusions: SHP1 and SHP2 are potential therapeutic targets for breast CSCs and gamma-T3 is a promising natural
drug for future breast cancer therapy.
Background
The concept of cancer stem cells (CSCs) describes that
tumors contain a small proportion of self-renewing and
pluri-potent cells that are responsible for initiating and
maintaining tumor growth [1]. This concept is well
established in leukemia and has also been reported in a
few solid tumor types [2–4]. Recent studies further con-
firm that a specific cell population is responsible for the
initiation and growth of solid tumors [5–7]. These cells
usually express high levels of multiple drug resistant
gene (MDR1) [8] and ATP binding cassette (ABC) trans-
porter [9] and are therefore resistant to chemotherapy
and considered as the major source of drug-resistance in
tumors. Moreover, it has been demonstrated that CSCs
are responsible for metastasis [7, 10, 11], which is an-
other major cause of cancer-related death. CSCs are
thus regarded as an essential target for future advanced
cancer therapy.
To achieve the goal of effective treatment of CSCs, iden-
tifying specific therapeutic targets is vital. Apart from high
throughput screening methods such as microarrays, iden-
tifying novel targets of inhibitors or natural drugs is an
alternative. A few natural compounds are reported to have
inhibitory effects on CSCs [12–14]. These products are
valuable for future CSC targeted therapy as they are nor-
mally less toxic than chemotherapeutic drugs. For ex-
ample, vitamin E isotype gamma tocotrienol (γ-T3) was
shown to be effective at inhibiting cancer cell growth in
several solid tumor models through apoptosis or cell stress
related pathways [15–18]. In CSCs, Ling and colleagues
reported that γ-T3 could effectively inhibit CSC growth in
prostate cancer in vitro and in vivo [19]. They also showed
that the CD44 expression of the CSCs was decreased by
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γ-T3 treatment. CD44 is one of the important epithelial
CSC markers, suggesting γ-T3 may affect the stemness of
prostate CSCs. However, the detailed mechanism of how
γ-T3 suppresses CD44 expression and prostate CSC
growth remains unknown. In addition, it is still not clear
whether the reduction of CD44 expression was through γ-
T3 directly interacting with CD44 or through an indirect
interaction with other molecules.
Previously, a study reported that γ-T3 inhibited STAT3
phosphorylation and JAK/STAT pathway activation in dif-
ferent melanoma cell lines, resulting in apoptosis of the
cancer cells [20]. This inhibition was through the induc-
tion of SHP1 expression by γ-T3, suggesting that SHP1
was a target of γ-T3 [20]. However, whether this is the
case in CSCs has not been reported or whether there are
any new targets in JAK/Stat pathway for γ-T3 remains un-
known. In JAK/Stat pathway, there are two very closely re-
lated proteins SHP1 and SHP2, they share highly similar
structures and sequences. Both of them have two Src
homology 2 domains (SH2) that bind to several tyrosine-
phosphorylated proteins [21–23]. For biological function,
however, SHP1 plays a dominant negative regulation role
in the pathway [24, 25] while SHP2 plays a major positive
role [26–28]. Phosphorylation of SHP2 activates associate
proteins such as Grb2 and Gab2 and form a protein com-
plex SHP2/Grb2/Gab2. This complex then activates the
downstream target RAS and other components of the
RAS/ERK pathways [29–31]. SHP2 is encoded by PTPN11,
a proto-oncogene in hematologic cells [32]. Mutation of
PTHN11 has been associated with juvenile myelomonocy-
tic leukemias, neuroblastoma, melanoma, acute myeloid
leukemia, breast cancer, lung cancer, and colorectal cancer
[33]. SHP2 protein levels are elevated in some cancers in-
cluding cervical cancer [34] and approx 72 % of breast
cancer cell lines [35]. Many cell types express SHP2 how-
ever, SHP1 is expressed in a restricted number of cell
types [36, 37]. These data indicate that compared with
SHP1, SHP2 is more likely to be an onco-protein involved
in cancer development. Indeed, several studies have
shown that inhibition of SHP2 can retard cancer cell
growth [38]. Inhibition of SHP2 gene expression with
shRNA was also associated with cell transformation from
mesenchymal to epithelial cells, indicating a promoting
role of SHP2 in carcinogenesis [39]. A recent study has
shown that SHP2 plays an essential role in the initiation,
progression, and metastasis of breast cancer by activating
stemness-associated transcription factors such as c-Myc
and ZEB1 [40], further demonstrating its oncogenic role
in cancer stem cells. However, there is no report on if γ-
T3 targets SHP2 in any cancer types.
Breast cancer is the leading cause of cancer related
death among women. Though some studies have
shown that using γ-T3 can effectively induce apoptosis
or cell cycle arrest in breast cancer cells [41, 18], there
is no report on γ-T3 treating breast CSCs. Particularly,
there is no report exploring the potential targets of SHP1
and SHP2 in breast CSCs. In this study, we have demon-
strated that γ-T3 had a broad inhibitory effect on human
epithelial CSCs including those from breast, colon, and
cervical cancers. We found that apart from the effect on
SHP1, γ-T3 also targeted SHP2 in breast cancer and that
the γ-T3 inhibitory effect on CSC growth was through the
RAS/ERK pathway. Moreover, we report here that the
level of phosphorylated SHP2 protein increases in breast
CSCs, compared with their parental cancer cells, suggest-
ing that SPH2 may play an important role in breast CSC
growth and may be considered as a potential therapeutic
target for breast CSCs.
Methods
Cell lines and mammosphere culture
This study did not involve in human subjects including
human material or human data. Epithelial cancer cell lines
of breast cancer MCF-7 (ATCC, HTB-22™), colon cancer
HCT-116 (ATCC, CCL-247™), and cervical cancer HeLa
(ATCC, CCL-2) were purchased from ATCC (during years
2010–2012) and maintained in complete Dulbecco’s
Modified Eagles Medium (DMEM, Invitrogen, Australia)
as previously described [42]. The sphere culture medium
was prepared as previously reported [43]. For the first pas-
sage of sphere culture, 1 × 104 cancer cells were seeded
into a T25 flask with 6 ml of sphere culture medium. Cells
were cultured in suspension for 4 days at 37 °C with 5 %
CO2 and an additional 2.5 ml of sphere culture medium
was added to the culture. The culture continued for an-
other 3–4 days and spheres were harvested by centrifu-
gation at 300 × g for 3 min and their numbers were
counted after re-suspension in 2–5 ml medium. For the
second and following passage sphere culture, the
spheres were treated with 1:1 diluted 2.5 % Trypsin-
EDTA (Invitrogen, Australia) for 5 min at 37 °C and
washed with sphere culture medium. Sphere cells were
separated by repeating pipetting. The separated cells
were passed through a cell strainer (40 μM, BD,
Australia) and were counted for continuous sphere cul-
ture or other assays in low-adherence 6-well plates
(Sigma-Aldrich, Australia) or T25 flasks.
γ-T3 treatment, flow cytometry, and fluorescence
microscopy
Highly purified γ-T3 was provided by Davos Life Science
Pte. Ltd, Singapore and was prepared as a stock solution in
100 % ethanol at a concentration of 20 mg/ml and stored
at −20 °C freezer. The stock solution was diluted in ethanol
into 2 mg/ml and added directly into the sphere cultural
medium at different concentrations. The control group was
added with same amount of ethanol. The cells were cul-
tured for 7–8 days until spheres formed. For FACS analysis,
Gu et al. BMC Cancer  (2015) 15:609 Page 2 of 11
cells were harvested, dispersed from spheres and stained
with antibodies to CD44 or CD133 conjugated with FITC
and CD24 conjugated with RPE (Invitrogen, Australia) at
concentrations of 1:100 (V/V, 5 × 105 cells). The cells were
washed 2 times with 1 % fetal calf serum (FCS)/PBS then
fixed with 2 % paraformaldehyde/PBS for FACS analysis
using Calibur or FACS Canto (BD, Australia).
Immuno-blotting
Immune-blotting analysis was conducted as previously
described [42]. The separated cells from mammospheres
and cell lysates were prepared in RIPA buffer after γ-T3
treatment. Before total protein measurement, the sam-
ples were sonicated briefly. Anti-human β-tubulin anti-
body was from Sigma-Aldrich. Anti-pERK antibody was
from Cell signaling. Rabbit anti-SHP2 antibody was
from Sigma-Aldrich and rabbit anti-SHP2 (pS576) poly-
clonal antibody was from Invitrogen USA. Mouse anti-
SHP1 antibody was purchased from Cell Signaling
Technology.
Real-time RT-PCR
Total RNA extraction from mammosphere cells was pre-
pared as instructed by the manufacturer using TRIzol® re-
agent (Invitrogen, Australia). Reverse transcription reactions
were performed with oligo-dT primer using the High Cap-
acity cDNA RT Kit (Applied Biosystems). Real-time PCR
was carried out with SYBR green master mixture (Pro-
mega) on a Rotor-Gene RG-3000 (Corbett Research,
Australia) with the program pre-heating 95 °C 10 min; then
40 cycles of 94 °C 15 s; 58 °C 30 s; and 72 °C 45 s. The
primers were: TGF-β-1: F 5′-CAACAATTCCTGGCGA-
TACC, R 5′-GAACCCG TTGATGTCCACTT; TGF-β-2: F
5′-GAGTGCCTGAACAACGGATT, R 5′-TGCAGCAGG-
GACA GTGTAAG; TGF-β-3: F 5′-GCAACTTGGAGGA-
GAACTGC, R 5′-CTGTGGGTTGTGTCTGC ACT; LIF:
F 5′-CCCTGTCGCTCTCTAAGCAC, R 5′-ATCCTGGA-
CAAGGGTGAGTG; H-Ras: F 5′-GTGGTCATTGATGGG-
GAGAC, R 5′-ACGTCATCCGAGTCCTTCAC; K-Ras: F
5′-TGT CAAGCTCAGCACAATCTG, R 5′-GGTAGG-
GAGGCAAGATGACA; ERBB2: F 5′-GACATTGACGA-
GACAGAG, R 5′-ACACAGTCACACCATAAC; ESR1: F
5′-CACATCAGGCACATGAGTAACAA, R 5′-TCCAGC
AGCAGGTCATAGAG; SHP1: F 5′ TTTCAAGAAGA
CGGGGATTG, R 5′ CGGACTCCTGCTTCTTGTTC;
SHP2: F 5′ AGAGCCACCCTGGAGATTTT, R 5′ CT
CCTCCACCAACGTCGTAT. The internal control was 18S
rRNA (F: 5′-CCATCGAACGTCTGCCCTA; R: 5′-TC
ACCCGTGGTCACCATG) is used to normalize target gene
expression.
Fig. 1 CD44 and CD24 expressions of mammosphere and MCF-7 cells: Mammosphere cells and their parental MCF-7 cells were labeled for CD44 and
CD24 expression. a antibody isotype controls of mammosphere cells. b mammosphere cells stained with CD44 and CD24 antibodies conjugated with
FITC and PE respectively. c an image of a mammosphere cultured for 8 days, the compacted sphere contains numerous cells. d MCF-7 cells stained
with isotype controls. e MCF-7 cells stained with CD44 and CD24 antibodies conjugated with FITC and PE respectively. f and g histogram diagrams to
show the CD24 (f) and CD44 (g) expression shifts (the decrease of CD24 and the increase of CD44 in mammosphere cells)
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Data analysis
Besides technical repeats (3 repeats) of real-time RT-
PCR, biological repeats (3 times) were performed. Data
collected from each (experimental and control) group
were expressed as mean ± SD. The one-way ANOVA
and unpaired t-test (GraphPad Prism 6 program) were
used to analyze the differences between groups and dis-
criminate the significant differences (two-tails, P < 0.05)
between experimental and control groups.
Results
Mammosphere cells and treatment with γ-T3
We used the reported sphere culture method [43, 44] to
culture mammospheres from breast carcinoma cell line
MCF-7. The mammosphere formation rate was about
20 % from the cell line in several generations (passages)
of culture. The mammosphere cells were separated and
characterized for surface expression of CD44 and CD24,
which are commonly considered as markers of breast
cancer stem cells [2]. The results showed CD44 expres-
sion increased in mammosphere cells and the positive
cell proportion increased from 5.62 % of parent MCF-7
cells to 45.65 % of mammosphere cells (Fig. 1). Mean-
while, the expression of CD24 alone and CD24/CD44
double positive cells was deceased from 15.58 to 5.99 %
and from 18.99 to 12.18 %, respectively (Fig. 1). These
profiles suggest that after sphere culture the mammo-
sphere cells are enriched for breast cancer stem-like
cells, which is consistent with previous reports [2, 45].
We then treated mammosphere cells with γ-T3 in
sphere culture by adding γ-T3 directly into the sphere
culture medium. As shown in Fig. 2, γ-T3 exhibited a
dose-dependent inhibition of the growth of mammo-
sphere cells and sphere formation from MCF-7 cells. At




Fig. 2 Dose-dependent inhibition of sphere growth of three epithelial cancers by γ-T3: a γ-T3 inhibited mammosphere formation and growth
from MCF-7 cells in a dose-dependent manner from 1.0 to 5.0 μg/ml. b morphology of mammosphere in vehicle control and in 5 μg/ml G-T3
treatment. c and d In addition to breast cancer, γ-T3 inhibited sphere formation of colon (HCT-116) and cervical (HeLa) cancers respectively
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γ-T3 inhibits spherical cell growth of other epithelial
cancers
To extend the above observations in breast cancer to
other epithelial cancers, we isolated sphere forming
cells (SFCs) from cervical (HeLa cells) and colon
(HCT-116 cells) cancers using the same sphere culture
method and analyzed their surface markers. The results
showed that these SFCs expressed specific markers as
expected (Additional file 1: Figure S1) which were con-
sistent with previous reports [44, 46], suggesting that
after sphere culture, CSCs are enriched in both cancer
cell lines. We treated these spherical cells with γ-T3.
Similar growth inhibition to mammospheres was ob-
served for these two cancers (Fig. 2c and d), revealing
that γ-T3 has a broad spectrum of inhibition effect on
the growth of CSCs in epithelial cancers, including
prostate cancer as reported previously [19]. In addition,
at a dose of 5.0 μg/ml the growth of CSCs was totally
inhibited (Fig. 2). It is also noted that comparisons
between the three epithelial cancers showed, cervical
CSCs from HeLa cells were slightly more sensitive to γ-
T3 than CSCs from MCF-7 and HCT-116 (Fig. 2).
γ-T3 targets SHP2 and also increases SHP1 protein levels
in mammosphere cells
To test whether SHP1 and/or SHP2 are affected by γ-T3
treatment, we firstly measured mRNA levels of SHP1
and SHP2 in γ-T3 treated mammosphere cells. SHP1
gene expression did not increase in a dose dependent
way as γ-T3 dose increased (Fig. 3a). But as we expected,
SHP2 gene expression did decrease in a dose dependent
manner (Fig. 3b). To confirm this in protein levels, we
measured total protein levels of SHP1 and SHP2 in γ-T3
treated mammosphere cells. As shown in Fig. 3c and d,
SHP1 levels increased while SHP2 levels decreased as γ-
T3 dose increased. To further prove that SHP2 bio-
logical function was inhibited by γ-T3 treatment, we also
measured phosphorylated SHP2 protein (p-SHP2) in γ-
A B
C D
Fig. 3 SHP 1 and SHP2 gene and protein expressions after γ-T3 treatment. a and b real-time PCR results showing SHP1 and SHP2 mRNA expression in
mammosphere cells treated with different doses of γ-T3. c and d Western blotting results showing SHP1 and SHP2 protein expression levels after γ-T3
treatment at different doses. EOH ethanol, SP sphere cells, Tub human β-tublin
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T3 treated cells, the result showed that p-SHP2 also de-
creased as γ-T3 dose increased (Fig. 4a). To further ex-
plore other possible targets of γ-T3, we measured the
expression of other two closely related genes, ERBB2
and ESR1. ERBB2 is also known as HER 2, and is a
trans-membrane receptor protein and an up-stream acti-
vator of SHP2 and RAS-ERK pathway [47]. ESR1 is an
estrogen receptor which can be associated with the cell
surface membrane and after activation can be involved
in the activation of MAPK [48]. However, our data indi-
cated that these two gene expressions were not affected
by γ-T3 treatment (Fig. 4b and c). Therefore, we focused
on SHP2 protein in this study.
Dose-dependent down-regulation of RAS/ERK pathway by
γ-T3
SH2-domain containing proteins, like SHP2, when phos-
phorylated on tyrosine residues, culminate in the activa-
tion of a number of intracellular signalling cascades
including the STAT5, Ras/mitogen activated protein kin-
ase (MAPK) and phosphoinositide-3 kinase (PI3K) path-
ways [49]. In this singling pathway Ras is a direct
downstream component of SHP2, hence we assumed
that the down-regulation of SHP2 would also affect Ras
gene expression. In addition, the increased SHP1 protein
expression by γ-T3 could also affect RAS/ERK pathway
through negatively regulating JAK/Stat pathway. We
thus measured Ras gene expression in γ-T3 treated cells.
As we expected, both H-Ras and K-Ras gene expressions
decreased as γ-T3 doses increased (Fig. 5a and b). To
further testify that γ-T3 targeted SHP1 and SHP2 and
through RAS/ERK pathway, we also measured another
downstream component, the phosphorylated ERK pro-
tein in γ-T3 treated cells and we found that phosphory-
lated ERK decreased in γ-T3 treated cells in a dose-
dependent manner (Fig. 5c). All these results together
suggest that SHP1, SHP2, and RAS/ERK pathways have
been affected by γ-T3 treatment. To understand if SHP2
is more activated in mammosphere cells, we compared p-
SHP2 level in MCF-7 and mammosphere cells (Fig. 5d).
The result indicated that an increased p-SHP2 was ob-
served in mammosphere cells.
γ-T3 did not affect self-renewal pathways in breast CSCs
It has been shown that TGF-β and LIF are two import-
ant self-renewal genes for stem cells [50, 51]. In cervical
cancer, we showed that silencing human papillomavirus
oncogenes E6/E7 with shRNA delivered by lentiviral
A
B C
Fig. 4 Phosphorylated SHP2 and other related gene expression after γ-T3 treatment. a Western blotting result shows phosphorylated SHP2 (p-SHP2)
protein levels in mammosphere cells after γ-T3 treatment with different doses. b and c, real-time RT-PCR results show mRNA expressions of ERBB and
ESR in γ-T3 treated mammosphere cells. EOH ethanol; SP sphere cells; Tub human β-tublin
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vector in cervical CSCs could lead to the down regula-
tion of self-renewal gene TGF-β [44]. To investigate if
γ-T3 also inhibits sphere growth through impairing
CSC self-renewal ability by down-regulating TGF-β
and LIF, we measured gene expression in MCF-7 and
mammosphere cells. However, the results failed to
show any dose-dependent reduction of gene expres-
sions (Fig. 6). To further confirm this, we also mea-
sured gene expression in HeLa sphere cells treated
with γ-T3 (Additional file 1: Figure S2). Similar results
were obtained in HeLa sphere cells, suggesting that γ-
T3 inhibits CSC growth was not through inhibiting
their self-renewal ability via TGF-β and LIF pathways.
This result also suggests that γ-T3 may specifically
target SHP1/SHP2/RAS/ERK pathways and which
probably leads to the inhibition of C-Myc and CyD
transcription factors and anti-apoptosis factor such as
Bcl-XL and Spred resulting in cell cycle arrest and
apoptosis of mammosphere cells (Fig. 7).
Discussion
In this study, based on the evidence that γ-T3 could ef-
fectively inhibit sphere growth in three different epithe-
lial cancers, we believed that its target(s) would be vital
for self-renewal and proliferation of CSCs and thus tried
to identify them. A previous study showed that in skin
cancer U266 and SCC4 cells, γ-T3 inhibited cell growth
through induction of SHP1 and suppression of its re-
lated JAK/STAT/RAS/ERK signaling pathway [20]. We
thought SHP1 could be also a target of γ-T3 in CSCs. In
addition, as SHP2 shares two SH2 domains with SHP1
but has opposite biological functions and is widely
expressed in many cell types compared to the restricted
expression of SHP1, we thought SHP2 could be a target
of γ-T3 as well. Indeed, our results proved that besides
increasing SHP1 protein levels, γ-T3 also targeted
PNPT11/SHP2 and inhibited their expression in mam-
mosphere cells in a dose dependent manner. As a conse-
quence of the dual effects of γ-T3, the downstream
A B
C D
Fig. 5 Ras/ERK signal pathway is down-regulated after γ-T3 treatment. As components of SHP2/RAS/ERK pathway, Ras gene expression including H-RAS
(a) and K-RAS (b) was decreased as γ-T3 dose increased from 0.5 to 3.0 μg/ml. c ERK protein levels decrease as γ-T3 dose increases. d Western result shows
the comparison of p-SHP2 protein level in MCF-7 cells and mammosphere cells (MCF-7-SP). Tub human β-tublin
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RAS/ERK signal pathway was down-regulated and this
further led to the possible cell cycle arrest and apoptosis
of mammosphere cells (Fig. 7). In contrast, other unre-
lated genes/pathways such as ERBB2, ESR1, and TGF-β
were not affected, indicating that SHP1 and SHP2 are
specific targets of γ-T3 in at least mammosphere cells.
As γ-T3 also effectively inhibits the spherical cell growth
of colon and cervical cancers, we assume their SHP1
and 2 had been affected. To our knowledge, the study of
the effect of γ-T3 on both SHP1 and SHP2 in mammo-
sphere cells has not been reported before. Particularly,
the down-regulation of PNPT11/SHP2 in mammo-
spheres by γ-T3 is a new finding. The implication of this
study is that SHP2 may serve as a target for breast CSC
therapy in the future. Our study also provides evidence
that γ-T3 can be considered as a promising therapeutic
candidate to target both SHP1/SHP2 in breast CSCs. As
treating breast cancer cells (eg. MCF-7) normally needs
a dose ranged from 10 to 40 μg/ml, if this dose is applied
in clinical settings, it will be sufficient to totally inhibit
breast CSC growth according to our present data.
Our results are consistent with a recent study in which
the authors demonstrated that SHP2 played a funda-
mental role in the initiation, progression, and metastasis
of human epidermal growth factor receptor 2 (HER2)-
positive and triple-negative breast cancers [40]. They
A B
C D
Fig. 6 Self-renewal genes of TGF-β and LIF expressions in mammosphere cells after γ-T3 treatment. Self-renewal gene expression of TGF-β (including
β1 to β3, a to c) and LIF (d) mRNA levels were not affected by γ-T3 treatment in a dose dependent way, suggesting these pathways may not be
involved in γ-T3 induced cell death
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showed that knockdown of SHP2 eradicated breast
tumour-initiating cells in xenograft models, and SHP2
depletion prevented invasion in three-dimensional cul-
tures and in a transductal invasion assay in vivo. In
addition, SHP2 knockdown in established breast tu-
mours blocked their growth and reduced metastasis
[40]. They also showed that these effects of SHP2 were
through activation of stemness-associated transcription
factors, including v-myc myelocytomatosis viral onco-
gene homolog (c-Myc) and zinc finger E-box binding
homeobox 1 (ZEB1). C-Myc is also a downstream com-
ponent of Ras/ ERK pathway, indicating their result is
consistent with our data. In addition, in the study they
showed that depletion of SHP2 could impair self-
renewal ability of breast cancer cells by using sphere
culture method [40]. This is obviously confirmed by
our current study. However, in our study we further
demonstrated that this was not through TGF-β and LIF
pathways (Fig. 6). All data above support our conclu-
sion and further prove that SHP2 provides a rationale
target for breast CSC therapy and γ-T3 should be con-
sidered as a good candidate drug for the therapy.
SHP2 is a member of the non-receptor protein-tyrosine
phosphatase family and its cell survival, proliferation, mi-
gration, and differentiation functions have been well char-
acterized in hematopoietic cells and hematopoietic stem
cells (HSCs). The loss of Ptpn11 in murine hematopoietic
cells can lead to bone marrow aplasia and lethality [36].
Mutant of Ptpn11 gene in mice show a rapid loss of HSCs
and immature progenitors of all hematopoietic lineages in
a gene dosage-dependent and cell-autonomous manner.
Ptpn11-deficient HSCs and progenitors undergo apoptosis
concomitant with increased Noxa expression. Mutant
HSCs/progenitors also show defective ERK and Akt acti-
vation in response to stem cell factors and diminished
thrombopoietin-evoked ERK activation [36]. Over-
expression of SHP2 was associated with leukemogenesis
in adult human leukemia [52]. Thus, Shp2 plays a critical
role in controlling the survival and maintenance of HSCs
and immature progenitors in vitro and in vivo.
Fig. 7 A schematic diagram to show SHP/RAS/ERK pathway and γ-T3 targets in mammosphere cells. In mammosphere cells, γ-T3 targets both
SHP1 and SHP2 to down regulate RAS/ERK pathway and subsequently leads to the cell death in mammospheres. For SHP1, γ-T3 promotes its
protein production to down-regulate Ras/ERK pathways. γ-T3 through down-regulating the protein level and phosphorylation of SHP2 reduces
the interaction with associated proteins such as GRB2 and GAB2, leading to activation of the RAS/ERK pathway. It is postulated that in the nucleus,
the double action of down-regulation of ERK interferes with the transcription factors C-myc and Cyd ensuring normal cell cycles (green arrows)
and the anti-apoptosis factors Bcl-XL and Spred subsequently cause cell cycle arrest and apoptosis of the mammosphere cells (Red arrows)
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SHP2 has been related to oncogenesis because like Src
(a well-known oncogene), PTNT11 is also reported as a
proto-oncogene [32]. It has been reported that the muta-
tion of PTPN11 is associated with high prevalence of
juvenile myelomonocytic leukemias, neuroblastoma, mel-
anoma, acute myeloid leukemia, breast cancer, lung can-
cer, and colorectal cancer [33]. Moreover, SHP2 protein is
elevated in some cancers including cervical cancer which
is high associated with HPV infection [34]. In breast can-
cer, 72 % cancer cell lines have increased amounts of the
SHP2 protein and dominant-negative SHP2 blocked the
growth of breast cancer cells [35]. Furthermore, overex-
pression of SHP2 appears to have a positive relationship
to HER2 overexpression, nuclear accumulation of hor-
mone receptors, higher tumour grade and lymph node
metastasis; which suggests that SHP2 promotes breast
oncogenesis [35]. In addition, SHP2 promotes HER2-
induced signalling and transformation at least in part by
dephosphorylating a negative regulatory autophosphoryl-
ation site [35, 40]. However we showed that γ-T3 induced
SHP2 reduction did not affect ERBB2/HER2 at mRNA
levels. Further investigations of protein levels are needed.
These results suggest that SHP2 might serve as a thera-
peutic target against breast cancer and other cancers char-
acterized by ERBB2/HER2 overexpression [53]. However,
SHP2 and its potential role in CSCs of solid tumors have
not been studied or reported much. In this study, we
showed that like in HSCs, p-SHP2 was expressed at higher
levels in mammosphere cancer cells compared with par-
ental MCF-7 cells, suggesting that it may play an import-
ant role in breast CSCs. This observation can be extended
to the spherical cells of two other epithelial tumors, colon
and cervix, which showed a similar mammosphere inhib-
ition, however further experimental data are needed to
prove this.
Conclusion
Apart from having confirmed the therapeutic value of
γ-T3, this study has also demonstrated that SHP2 is a
potential biomarker and therapeutic target for breast
CSCs. In addition, it seems that this target may be
widely distributed in other epithelial CSCs including
colon, cervical and probably prostate cancers. From
the therapeutic point of view, γ-T3 has the potential
to be an effective drug to target both differentiated
cancer cells and CSCs, which is better than conven-
tional chemotherapeutic drugs that only target differ-
entiated cancer cells.
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